Cardiovascular risk and triptan usage among patients with migraine
Abstract
BACKGROUND: Migraine, a neurovascular disorder evident by recurrent headaches, is associated with increased risk of ischemic vascular events, including ischemic stroke and myocardial infarction. Triptans, acute migraine-specific treatment, cause vasoconstriction, complicating treatment decisions, especially for patients with migraine with cardiovascular risk factors. This study examined associations between triptan usage and cardiovascular (CV) events in patients with migraine.
METHODS: This retrospective, population-based cohort study conducted in southern Israel utilized data from Clalit Health Services. Electronic medical records from January 2000 to January 2022 were analyzed to assess triptan usage and CV events within 90 days post-purchase among patients aged ≥18 years with a diagnosis of migraine based on International Classification of Diseases, Ninth Revision codes or triptan claims. Sensitivity analyses accounted for varying timeframes and usage patterns.
RESULTS: Among 26,054 patients with migraine, 12,560 (48.2%) initiated triptan therapy. The prevalence of CV risk factors including dyslipidemia, diabetes mellitus, hypertension, smoking, atrial fibrillation, and obesity was higher in the non-triptan group (standardized mean difference [SMD] = 0.028-0.289). The mean (standard deviation) number of triptan pills used per month was 1.9 (1.5), with most patients (89.5%) using 1-4 pills/month. CV events within 90 days occurred slightly more in the triptan group (5.1%)…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 26,054 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.